Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genzyme, a Sanofi Company
Age
16–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have successfully completed the previous double-blind study (AGAL-1-002-98)
Patients must provide written informed consent prior to study participation
Female patients must have a negative pregnancy test prior to each dosing and use a medically accepted method of contraception throughout the study
You may not be if
Patient has undergone kidney transplant or is currently on dialysis
Patient is pregnant or lactating
Patient is unwilling to comply with the requirements of the protocol
Patient has a clinically significant organic disease (with the exception of symptoms related to Fabry disease), including clinically significant cardiovascular, hepatic, pulmonary, neurologic, or renal disease, or other medical condition, serious intercurrent illness, or extenuating circumstances that, in the opinion of the investigator, would preclude participation in the study
Clareo Health | A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
